The Golden Window How an Experimental Nasal Spray Could Change Stroke Care
When a stroke strikes, every minute matters.
An ischemic stroke occurs when a blood clot blocks blood flow to part of the brain. Without enough oxygen and glucose, brain cells begin to malfunction and eventually die. The longer circulation remains blocked, the greater the potential for permanent disability.
That is why modern stroke medicine is built around speed.
But researchers are now investigating a different idea: instead of trying only to reopen the blocked blood vessel, could doctors temporarily protect vulnerable brain tissue while the clot is being treated?
A team involving researchers at the University of Copenhagen has been studying an experimental approach using NA-1, also known as nerinetide, a peptide designed to interfere with damaging signals involved in excitotoxicity. Their recent work explored whether delivering NA-1 through the nose could improve its access to the brain.
The findings are promising—but they are not yet a new stroke treatment.
Why protecting the brain is so difficult
After an artery becomes blocked, the affected brain is not simply divided into “dead” and “healthy” tissue.
At the center of the stroke is the most severely deprived tissue, often called the ischemic core. Surrounding it is a zone known as the penumbra.
The penumbra has reduced blood flow but may remain viable for a period of time, depending on factors such as collateral circulation and the location and size of the blockage.
This area is one of the major targets of stroke research.
Even when blood flow is severely reduced, neurons can suffer from a chain reaction involving excessive glutamate signalling, calcium overload, oxidative stress and other damaging processes. Researchers have therefore spent decades looking for ways to interrupt these pathways and preserve threatened brain cells.
The challenge has been getting the right medicine to the brain at the right time.
The blood-brain barrier problem
The brain has an extraordinarily selective protective system called the blood-brain barrier. It helps keep potentially harmful substances in the bloodstream away from delicate neural tissue.
That protection is essential—but it can also make drug delivery difficult.
NA-1 was developed to interfere with the interaction between PSD-95 and NMDA-receptor signalling, a pathway involved in excitotoxic neuronal injury. Earlier laboratory and animal studies suggested that disrupting this pathway could reduce brain injury after ischemia.
But translating those results into human treatment has been difficult.
Importantly, the story of NA-1 also demonstrates why promising laboratory findings must be interpreted carefully. In the large ESCAPE-NA1 clinical trial, intravenous nerinetide did not improve overall clinical outcomes in patients undergoing thrombectomy, although researchers identified potentially important subgroup findings.
The new Copenhagen research is therefore exploring a different question: could changing the route of delivery change how much of the peptide reaches the brain?
Could the nose provide a shortcut?
The upper nasal cavity has connections with pathways associated with the olfactory system and trigeminal nerves. Researchers have been investigating these routes as potential ways of delivering medicines toward the central nervous system.
In the Copenhagen study, nasal administration of NA-1 in mice resulted in measurable brain uptake, particularly in the olfactory bulb. Certain cell-penetrating peptides increased delivery in the experimental model, while nasal administration produced less off-target tissue distribution than intravenous administration.
That is an interesting proof of concept.
But it does not mean that a nasal spray can currently be given to someone having a stroke at home.
The study did not establish that a spray preserves human brain function, prevents disability, or buys patients hours of extra treatment time.
Those questions require human clinical trials.
Why this could matter especially for older adults
Stroke becomes increasingly important with age, and older adults may also have several conditions—such as high blood pressure, diabetes, atrial fibrillation or vascular disease—that increase stroke risk.
For families, one of the most important lessons from this research is therefore not to wait for the experimental technology.
Current stroke treatment is already becoming faster and more flexible.
The 2026 American Heart Association/American Stroke Association guideline expanded recommendations around clot-removal procedures and supports either tenecteplase or alteplase for eligible patients within the appropriate treatment window. It also emphasizes rapid brain imaging and coordinated emergency systems.
For some patients, mechanical thrombectomy can dramatically change the outcome by physically removing a large clot.
A future neuroprotective treatment could potentially become an additional tool, rather than a replacement for clot removal or clot-busting therapy.
The question scientists still have to answer
The biggest hurdle is translation.
A nasal delivery system that works in mice may behave very differently in humans. The anatomy of the human nasal cavity is different, and researchers must determine how reliably a therapeutic dose can reach the intended tissue.
They also need to establish safety, appropriate dosing, timing, interactions with existing stroke treatments and—most importantly—whether the approach actually improves meaningful outcomes such as independence, movement, speech and cognition.
That is a much higher bar than simply demonstrating that a molecule reaches the brain.
And history provides a warning: many neuroprotective treatments have produced encouraging results in laboratory models without becoming successful human stroke therapies.
The most important stroke treatment is still recognition
While researchers work on tomorrow’s therapies, today’s most valuable intervention remains remarkably simple: recognize the symptoms and call emergency services immediately.
The American Stroke Association is now using B.E. F.A.S.T. in its public stroke education:
B — Balance: sudden dizziness or loss of coordination.
E — Eyes: sudden trouble seeing.
F — Face: one side of the face droops.
A — Arm: sudden weakness or numbness, especially on one side.
S — Speech: sudden slurring, confusion or difficulty speaking.
T — Time: call emergency services immediately.
Do not wait for symptoms to disappear.
Do not assume that an older person’s sudden confusion, weakness or speech problem is simply “getting older.” Stroke symptoms require urgent medical assessment.
A promising idea, not a miracle spray
The Copenhagen research offers something genuinely interesting: a possible way of delivering a neuroprotective peptide toward the brain through the nose.
But the word experimental matters.
There is currently no approved nasal spray that allows people to treat an acute stroke at home or in an ambulance. The research has not established that such a treatment can replace emergency imaging, thrombolysis or thrombectomy.
What it does provide is another direction for scientists trying to solve one of stroke medicine’s oldest problems: how to keep threatened brain tissue alive long enough for doctors to restore blood flow.
If future human trials succeed, the significance could be substantial.
For now, however, the golden window remains what it has always been: the time between the first warning sign and professional treatment.
And when that window opens, the safest response is still the fastest one.
Photo by Pavel Danilyuk: https://www.pexels.com/photo/sick-man-in-white-shirt-wiping-his-nose-with-tissue-7596886/
About Wellcore Weekly: Wellcore Weekly covers health, wellness, nutrition, sleep, fitness, and medical research with timely, easy-to-understand updates for everyday readers.
